Cardiovascular diseases are the leading cause of death for patients with diabetes: among these patients, in fact, the main cardiovascular risk factors are more frequent and result in more serious consequences than the general population.
In the treatment of type 2 diabetes, optimal management of glycemic values is the first level of therapy and represents the foundation of the profession of diabetologist. However, nowadays it appears more and more evident and important for the doctor to evaluate the high impact that cardiovascular diseases have on diabetes and on the management of this disease and consequently, consider this fundamental aspect in choosing the best drug therapy for the diabetic patient.
The new therapeutic options for type 2 diabetes are presented to the diabetologist as innovative solutions able to offer beyond the glycemic control, a proven protection from cardiovascular risk.
Recent studies have evaluated and demonstrated the effects of long-term treatment of some of these drugs on cardiovascular morbidity and mortality.
The most recent Italian guidelines (Italian standards for the treatment of diabetes mellitus 2018) have accepted the new scientific evidence and proposed a new algorithm for the treatment of type 2 diabetes that includes the most important classes of innovative drugs with particular attention to those with proven effectiveness in terms of cardiovascular protection.
A training course was held in our Goldoni Room on 11 and 12 October, which will allow participants to deepen the link between type 2 diabetes and cardiovascular risk, implementing knowledge of the new classes of drugs and their use in patient care diabetic.
The initiative is an interactive training project, of national importance, whose goal is to give the diabetologist the new evidence on type 2 diabetes and cardiovascular protection, with particular regard to the class of SGLT2 inhibitors.
For more information, contact:
ABOUT EVENTS SRL
Tel. 0039 02 89634651
www.aboutevents.eu
